Enterprise Value
97.91M
Cash
1.124B
Avg Qtr Burn
-76.9M
Short % of Float
8.16%
Insider Ownership
9.52%
Institutional Own.
96.51%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bavdegalutamide (ARV-110) (PROTAC protein degrader) Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s | Phase 3 Initiation | |
ARV-471 (oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Initiation | |
ARV-766 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 1 Data readout |